Taewoong Choi
Assistant Professor of Medicine
Based on my prior experience in basic/translational immunology research and clinical hematopoietic stem cell transplantation, I am interested in early phase clinical protocols for novel immunotherapy of hematologic malignancies.
Current Appointments & Affiliations
- Assistant Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2020
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2019
Contact Information
- 2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
- DUMC Box 3961, Durham, NC 27710
-
taewoong.choi@duke.edu
(919) 668-1000
- Background
-
Education, Training, & Certifications
- Postdoctoral Research Fellow on T32 Training Grant, Stanford University, School of Medicine 2016 - 2017
- BMT Fellowship, Stanford University, School of Medicine 2015 - 2016
- Hematology/Oncology Fellowship, University of Pittsburgh, School of Medicine 2012 - 2015
- Internship and Residency in Internal Medicine, St. Luke's Memorial Hospital Center 2009 - 2012
- M.D., Seoul National University (South Korea) 2002
-
Medical Licensure
- 2017-00624. North Carolina. 2017
-
Duke Appointment History
- Medical Instructor in the Department of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2017 - 2020
- Recognition
-
Awards & Honors
- Expertise
-
Subject Headings
- Research
-
Selected Grants
- Long Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells awarded by Celgene Corporation 2021 - 2026
- A Phase I, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 as a single agent in relapsed or refractory hematological malignancies and in combgination with Daratumumab as a Salvage Regimen for Multiple Myeloma awarded by Nektar Therapeutics 2020 - 2025
- Prospective, Multicenter, Open-Label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity in Subjects with Relapsed or Refractory Diffuse Large B- awarded by Jazz Pharmaceuticals 2019 - 2024
- A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KARMMa-3) awarded by Celgene Corporation 2019 - 2024
-
Fellowships, Supported Research, & Other Grants
- KarMMa-3: a phase 3, multicenter, randomized, open-label study to compare the efficacy and safety of bb2121 versus standard triplet regimens in subjects with relapsed and refractory multiple myeloma awarded by Celgene 2019
- Prospective, Multicenter, Open-Label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in Prevention of CAR-T associated Neurotoxicity in Subjects with Relapsed or Refractory DLBCL receiving Axicabtagene Ciloleucel (Yescarta®) awarded by Jazz Pharmaceutical 2019
-
External Relationships
- Janssen Pharmaceuticals
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Racioppi, A., Dalton, T., Ramalingam, S., Romero, K., Ren, Y., Bohannon, L., … Sung, A. D. (2021). Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients. Transplantation and Cellular Therapy, 27(2), 181.e1-181.e9. https://doi.org/10.1016/j.jtct.2020.10.017Full Text
-
Choi, T., Choi, I. Y., Han, K., Jeong, S.-M., Yoo, J. E., Rhee, S. Y., … Shin, D. W. (2021). Lipid Level, Lipid Variability, and Risk of Multiple Myeloma: A Nationwide Population-Based Study of 3,527,776 Subjects. Cancers (Basel), 13(3). https://doi.org/10.3390/cancers13030540Full Text Link to Item
-
Jeong, S.-M., Choi, T., Kim, D., Han, K., Kim, S. J., Rhee, S. Y., … Shin, D. W. (2020). Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy. Leukemia. https://doi.org/10.1038/s41375-020-01081-5Full Text Link to Item
-
Smith, P., Thompson, J. C., Perea, E., Wasserman, B., Bohannon, L., Racioppi, A., … Sung, A. D. (2020). Clinical and Neuroimaging Correlates of Post-Transplant Delirium. Biol Blood Marrow Transplant, 26(12), 2323–2328. https://doi.org/10.1016/j.bbmt.2020.09.016Full Text Link to Item
-
Maung, K., Ramalingam, S., Chaudhry, M., Ren, Y., Jung, S.-H., Romero, K., … Sung, A. D. (2020). Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality. Plos One, 15(9), e0238824. https://doi.org/10.1371/journal.pone.0238824Full Text Link to Item
-
Choi, T. (2019). Is autologous stem cell transplantation still relevant for multiple myeloma? Curr Opin Hematol, 26(6), 386–391. https://doi.org/10.1097/MOH.0000000000000538Full Text Link to Item
-
Diwakar, D., Choi, T., Tawbi, T. H., & Kirkwood, J. M. (2014). RE: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Annals of Oncology, 25(8), 1670–1671. https://doi.org/10.1093/annonc/mdu196Full Text
-
Choi, T., Ferris, S. T., Matsumoto, N., Poursine-Laurent, J., & Yokoyama, W. M. (2011). Ly49-Dependent NK Cell Licensing and Effector Inhibition Involve the Same Interaction Site on MHC Ligands. The Journal of Immunology, 186(7), 3911–3917. https://doi.org/10.4049/jimmunol.1004168Full Text
-
Yoo, J. H., Jang, S. A., & Choi, T. (2010). Sociocultural Determinants of Negative Emotions Among Dementia Caregivers in the United States and in Korea: A Content Analysis of Online Support Groups. Howard Journal of Communications, 21(1), 1–19. https://doi.org/10.1080/10646170903501195Full Text
-
Kim, S., Sunwoo, J. B., Yang, L., Choi, T., Song, Y.-J., French, A. R., … Yokoyama, W. M. (2008). HLA alleles determine differences in human natural killer cell responsiveness and potency. Proceedings of the National Academy of Sciences, 105(8), 3053–3058. https://doi.org/10.1073/pnas.0712229105Full Text
-
-
Conference Papers
-
Maung, K., An Chao, N. J., Corbet, K., Engemann, A. M., Gasparetto, C., Horwitz, M., … Choi, T. (2020). CLO20-049: Retrospective Study of Safety and Toxicity Profile Comparison for Propylene Glycol-Free Melphalan (Evomela®) and Generic Melphalan. In Journal of the National Comprehensive Cancer Network (Vol. 18, pp. CLO20-049). Harborside Press, LLC. https://doi.org/10.6004/jnccn.2019.7412Full Text
-
Ramalingam, S., Siamakpour-Reihani, S., Bohannon, L., Ren, Y., Sibley, A., Nixon, A., … Sung, A. D. (2020). Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT. In Biology of Blood and Marrow Transplantation (Vol. 26, pp. S48–S49). Orlando, FL: ELSEVIER SCIENCE INC.Link to Item
-
Smith, P. J., Lew, M., Lowder, Y. P., Romero, K., Thompson, J., Bohannen, L., … Sung, A. D. (2020). Cognitive Impairment in Candidates for Allogeneic Hematopoietic Stem Cell Transplantation. In Biology of Blood and Marrow Transplantation (Vol. 26, pp. S241–S241). Orlando, FL: ELSEVIER SCIENCE INC.Link to Item
-
Bohannon, L. M., Page, K. M., Ren, Y., Jung, S.-H., Giri, V. K., Lew, M. V., … Sung, A. D. (2019). Decreased Mortality after the First Year of Allogeneic Hematopoietic Stem Cell Transplant in Recipients of Umbilical Cord Blood Vs. Matched Related or Matched Unrelated Donors. In Blood (Vol. 134, pp. 4613–4613). American Society of Hematology. https://doi.org/10.1182/blood-2019-126906Full Text
-
Giri, V. K., Kegerreis, K. G., Ren, Y., Bohannon, L. M., Lobaugh-Jin, E., Messina, J. A., … Sung, A. D. (2019). Daily Chlorhexidine Gluconate Bathing Reduces the Rate of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Stem Cell Transplantation. In Blood (Vol. 134, pp. 2210–2210). American Society of Hematology. https://doi.org/10.1182/blood-2019-122272Full Text
-
Lew, M. V., Ren, Y., Lowder, Y. P., Romero, K. M., Thompson, J. C., Bohannon, L. M., … Sung, A. D. (2019). Geriatric Assessment Identifies Impairments in Younger Candidates for Allogeneic Hematopoietic Stem Cell Transplantation. In Blood (Vol. 134, pp. 1984–1984). American Society of Hematology. https://doi.org/10.1182/blood-2019-127264Full Text
-
Maung, K. K. K., Chaudhry, M., Ren, Y., Jung, S.-H., Romero, K. M., Corbet, K., … Sung, A. D. (2019). Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality. In Blood (Vol. 134, pp. 5731–5731). American Society of Hematology. https://doi.org/10.1182/blood-2019-121830Full Text
-
Choi, T., Kodali, M. K., & Weng, W.-K. (2017). Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma. In Biology of Blood and Marrow Transplantation (Vol. 23, pp. S263–S264). Elsevier BV. https://doi.org/10.1016/j.bbmt.2016.12.426Full Text
-
Choi, T., Poursine‐Laurent, J., Matsumoto, N., & Yokoyama, W. (2008). Interaction sites on H2Dd for Ly49A‐dependent natural killer (NK) cell licensing. In The Faseb Journal (Vol. 22, pp. 672.37-672.37). San Diego, CA, USA: Federation of American Society of Experimental Biology. https://doi.org/10.1096/fasebj.22.1_supplement.672.37Full Text
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.